

**PATIENT NAME: RESHMA RAI** REF. DOCTOR: DR. SAJJAN SHENOY

CODE/NAME & ADDRESS: C000135696 ACCESSION NO: 0298YD005491 AGE/SEX :46 Years Female

DOOR NO. 24-11-1132/1 (2) SHOP GROUND FLOOR

SHRI DURGA COMPLEX, MARNAMIKATTE JUNCTION

DAKSHINA KANNADA 575001

8088208348

PATIENT ID : RESHF140678298

CLIENT PATIENT ID: ABHA NO

:17/04/2025 07:51:42 RECEIVED: 17/04/2025 10:30:27

REPORTED :17/04/2025 13:14:33

**Test Report Status** Results **Biological Reference Interval** Units **Final** 

BIOCHEMISTRY - LIPID						
LIPID PROFILE						
CHOLESTEROL, TOTAL	205 High	Desirable: <200 BorderlineHigh : 200-239 High : > or = 240	mg/dL			
TRIGLYCERIDES	113	Desirable: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High: > or = 500	mg/dL			
HDL CHOLESTEROL	44	< 40 Low > or = 60 High	mg/dL			
LDL CHOLESTEROL, DIRECT	150 High	Adult levels: mg/dL Optimal < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190				
NON HDL CHOLESTEROL	161 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL			
VERY LOW DENSITY LIPOPROTEIN	22.6	< or = 30.0	mg/dL			
CHOL/HDL RATIO	4.7 High	3.30 - 4.40				
LDL/HDL RATIO	3.4 High	0.5 - 3.0				

## Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	· · · · · · · · · · · · · · · · · · ·
Extreme risk group	A.CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease



**G S BALASUBRAMANYAM CONSULTING BIOCHEMIST** 

Dr.CHANDRAYYA ACHARY, MD (PATH) **CONSULTANT PATHOLOGIST** 





Page 1 Of 3

Karnataka, India Tel: 9111591115





**PATIENT NAME: RESHMA RAI** REF. DOCTOR: DR. SAJJAN SHENOY

CODE/NAME & ADDRESS: C000135696 ACCESSION NO: 0298YD005491 AGE/SEX :46 Years Female

DOOR NO. 24-11-1132/1 (2) SHOP GROUND FLOOR SHRI DURGA COMPLEX, MARNAMIKATTE JUNCTION

DAKSHINA KANNADA 575001

8088208348

PATIENT ID : RESHF140678298

CLIENT PATIENT ID: ABHA NO

:17/04/2025 07:51:42

RECEIVED: 17/04/2025 10:30:27 REPORTED :17/04/2025 13:14:33

**Test Report Status** Results **Biological Reference Interval** Units **Final** 

Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.			
	Familial Homozygous Hypercholesterolemia			
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ			
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary			
	Artery Calcium - CAC > 300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
Moderate Risk	2 major ASCVD risk factors			
Low Risk	0-1 major ASCVD risk factors			
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors				
1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females		3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD		4. High blood pressure		
5. Low HDL				

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	$\langle OR = 30 \rangle$	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

> \*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

**G S BALASUBRAMANYAM CONSULTING BIOCHEMIST** 

Dr.CHANDRAYYA ACHARY, MD (PATH) **CONSULTANT PATHOLOGIST** 





Page 2 Of 3



Karnataka, India Tel: 9111591115





PATIENT NAME: RESHMA RAI REF. DOCTOR: DR. SAJJAN SHENOY

CODE/NAME & ADDRESS : C000135696

DIA NEED

DOOR NO. 24-11-1132/1 (2) SHOP GROUND FLOOR SHRI DURGA COMPLEX, MARNAMIKATTE JUNCTION

DAKSHINA KANNADA 575001

8088208348

ACCESSION NO : 0298YD005491

PATIENT ID : RESHF140678298

CLIENT PATIENT ID: ABHA NO : AGE/SEX :46 Years Female DRAWN :17/04/2025 07:51:42

RECEIVED : 17/04/2025 10:30:27 REPORTED :17/04/2025 13:14:33

Test Report Status <u>Final</u> Results Biological Reference Interval Units

## **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

**Agilus Diagnostics Ltd** 

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Gran

G S BALASUBRAMANYAM CONSULTING BIOCHEMIST

Dr. CHANDRAYYA

Dr.CHANDRAYYA ACHARY, MD (PATH) CONSULTANT PATHOLOGIST





Page 3 Of 3

View Details

View Report



Karnataka, India Tel: 9111591115

